Out of control: Blinding, dose response, and psychosocial controls in psychedelic trials

Summary

As psychedelic clinical trials grow, fundamental design problems become clearer. Blinding fails because participants and therapists can easily tell who received a psychedelic due to its strong subjective effects, which are themselves considered therapeutically relevant. Alternative controls, such as dose-response designs, offer a practical workaround. The role of psychotherapy in psychedelic treatment remains ambiguous and poorly defined. The authors argue that preserving traditional placebo-controlled frameworks is inadequate and instead propose graded dose comparisons and unblinded comparative efficacy studies. They also outline a plan to empirically isolate psychotherapy's contribution, calling for operational definitions, fidelity monitoring, and risk mitigation. Progress will require triangulating evidence across multiple imperfect but complementary methods.

Study at a glance

Abstract

As psychedelic clinical trials expand in scale and influence, foundational challenges in trial design have come into sharper focus. In this commentary, we examine three interrelated issues: 1) the failure of blinding in psychedelic trials, 2) the potential of alternate controls including dose-response designs as an empirical workaround, and 3) the persistent ambiguity surrounding psychosocial control conditions. We argue that efforts to preserve traditional placebo-controlled frameworks are often inadequate due to the unmistakable subjective effects of psychedelics and the therapeutic relevance of those effects themselves. Instead, we highlight alternative designs including graded dose comparisons and unblinded comparative efficacy studies as pragmatic paths forward. Finally, we outline a proposal for empirically isolating the role of psychotherapy in psychedelic treatment, emphasizing the need for operational definitions, fidelity monitoring, and careful risk mitigation. These issues are unlikely to be resolved by any single design; rather, progress will require triangulating evidence across multiple imperfect but complementary methodologies.